ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

ASCO Urges NCI To Spell Out Metrics of Success Beyond Cutting Groups to Arbitrary Number

June 17, 2011

Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study

December 31, 2010

Fisher Committee Suggest Program, NCI Changes To Enhance Surgical Oncology

April 1, 1977

Waksals Keep ImClone Jobs, BMS Pumps $200M Into C225

March 8, 2002

NCI’s Professional Judgment Budget Outlines Spending of $7.2 Billion

February 13, 2009

ACS Unveils Plan For Combating Tobacco Marketing

May 18, 1990